



May 8, 2017

Immune Design to Report First Quarter 2017 Financial Results & Provide Corporate Update

SEATTLE and SOUTH SAN FRANCISCO, Calif., May 08, 2017 (GLOBE NEWSWIRE) -- Immune Design (Nasdaq:IMDZ), a clinical-stage immunotherapy company focused on cancer, today announced that it will report first quarter 2017 financial results and provide a corporate update after the close of U.S. financial markets on Wednesday, May 17, 2017. Immune Design management will host a webcast and conference call at 2:00 p.m. Pacific Time / 5:00 p.m. Eastern Time on May 17, 2017.

The live call may be accessed by dialing 844-266-9538 for domestic callers and 216-562-0391 for international callers. A live webcast of the call will be available online from the investor relations section of the company website at <http://ir.immunedesign.com/events.cfm> and will be archived there for 30 days. A telephone replay of the call will be available for five days by dialing 855-859-2056 for domestic callers or 404-537-3406 for international callers and entering the conference code: 20090178.

About Immune Design

Immune Design is a clinical-stage immunotherapy company employing next-generation *in vivo* approaches to enable the body's immune system to fight disease. The company's technologies are engineered to activate the immune system's natural ability to generate and/or expand antigen-specific cytotoxic T cells, while also enhancing other immune effectors, to fight cancer and other chronic diseases. CMB305 and G100, the primary foci of Immune Design's ongoing immunology clinical programs, are products of its two synergistic discovery platforms, ZVex[®] and GLAAS[®]. Immune Design has offices in Seattle and South San Francisco. For more information, visit www.immunedesign.com.

Media Contact

Julie Rathbun
Rathbun Communications
julie@rathbuncomm.com
206-769-9219

Investor Contact

Shari Annes
Annes Associates
sannes@annesassociates.com
650-888-0902